Announcement on Acceptance of First Generic Application for Tirzepatide Injection

Hybio Pharmaceutical Co., Ltd.·August 7, 2026·2 pages

✨ AI Summary

Shenzhen Han Yu Pharmaceutical Co., Ltd. announced that its first generic application for Tirzepatide Injection has been accepted by the NMPA. This drug is used for type 2 diabetes and long-term weight management. The company is the first domestic applicant for this product, which has significant market potential.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300199

Securities Abbreviation: Han Yu Pharmaceutical

Announcement No.: 2026-051

Shenzhen Han Yu Pharmaceutical Co., Ltd.

Announcement on Acceptance of First Generic Application for Tirzepatide Injection

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Shenzhen Han Yu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Han Yu Pharmaceutical") recently received the "Acceptance Notice" for Tirzepatide Injection issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Drug Information

Drug Name: Tirzepatide Injection

Dosage Form: Injection

Specifications: Calculated as C225H348N48O68 (1) 0.5ml: 2.5mg (2) 0.5ml: 5mg (3) 0.5ml: 7.5mg (4) 0.5ml: 10mg

Application Matter: Marketing authorization for domestic

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.